These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 8819132)
41. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079 [TBL] [Abstract][Full Text] [Related]
42. Partial loss of dopaminergic neurons in the substantia nigra, ventrotegmental area and the retrorubral area -- model of the early beginning of Parkinson's symptomatology? Heim C; Sova L; Kurz T; Kolasiewicz W; Schwegler H; Sontag KH J Neural Transm (Vienna); 2002 May; 109(5-6):691-709. PubMed ID: 12111461 [TBL] [Abstract][Full Text] [Related]
43. Synaptic changes in the striatum of schizophrenic cases: a controlled postmortem ultrastructural study. Kung L; Conley R; Chute DJ; Smialek J; Roberts RC Synapse; 1998 Feb; 28(2):125-39. PubMed ID: 9450513 [TBL] [Abstract][Full Text] [Related]
44. Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study. Freund TF; Bolam JP; Björklund A; Stenevi U; Dunnett SB; Powell JF; Smith AD J Neurosci; 1985 Mar; 5(3):603-16. PubMed ID: 2857778 [TBL] [Abstract][Full Text] [Related]
45. Monosynaptic input from the nucleus accumbens--ventral striatum region to retrogradely labelled nigrostriatal neurones. Somogyi P; Bolam JP; Totterdell S; Smith AD Brain Res; 1981 Aug; 217(2):245-63. PubMed ID: 7248789 [TBL] [Abstract][Full Text] [Related]
46. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Damier P; Hirsch EC; Agid Y; Graybiel AM Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830 [TBL] [Abstract][Full Text] [Related]
47. Perforated synapses on double-headed dendritic spines: a possible structural substrate of synaptic plasticity. Geinisman Y; Morrell F; deToledo-Morrell L Brain Res; 1989 Feb; 480(1-2):326-9. PubMed ID: 2713659 [TBL] [Abstract][Full Text] [Related]
48. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989 [TBL] [Abstract][Full Text] [Related]
49. Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson's disease. Bensaid M; Michel PP; Clark SD; Hirsch EC; François C Exp Neurol; 2016 Jan; 275 Pt 1():209-19. PubMed ID: 26571193 [TBL] [Abstract][Full Text] [Related]
50. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Liang CL; Wang TT; Luby-Phelps K; German DC Exp Neurol; 2007 Feb; 203(2):370-80. PubMed ID: 17010972 [TBL] [Abstract][Full Text] [Related]
51. Functional changes in the frontal cortex in Parkinson's disease using a rat model. Hou Z; Lei H; Hong S; Sun B; Fang K; Lin X; Liu M; Yew DT; Liu S J Clin Neurosci; 2010 May; 17(5):628-33. PubMed ID: 20116257 [TBL] [Abstract][Full Text] [Related]
52. Neurotensin terminals form synapses primarily with neurons lacking detectable tyrosine hydroxylase immunoreactivity in the rat substantia nigra and ventral tegmental area. Woulfe J; Beaudet A J Comp Neurol; 1992 Jul; 321(1):163-76. PubMed ID: 1351897 [TBL] [Abstract][Full Text] [Related]
54. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment. Hirsch EC Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138 [TBL] [Abstract][Full Text] [Related]
55. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Anichtchik OV; Rinne JO; Kalimo H; Panula P Exp Neurol; 2000 May; 163(1):20-30. PubMed ID: 10785440 [TBL] [Abstract][Full Text] [Related]
56. Neuronal inhibition and synaptic plasticity of basal ganglia neurons in Parkinson's disease. Milosevic L; Kalia SK; Hodaie M; Lozano AM; Fasano A; Popovic MR; Hutchison WD Brain; 2018 Jan; 141(1):177-190. PubMed ID: 29236966 [TBL] [Abstract][Full Text] [Related]
57. Ultrastructural immunocytochemical localization of mu-opioid receptors in dendritic targets of dopaminergic terminals in the rat caudate-putamen nucleus. Wang H; Moriwaki A; Wang JB; Uhl GR; Pickel VM Neuroscience; 1997 Dec; 81(3):757-71. PubMed ID: 9316027 [TBL] [Abstract][Full Text] [Related]
58. Loss and remodeling of striatal dendritic spines in Parkinson's disease: from homeostasis to maladaptive plasticity? Villalba RM; Smith Y J Neural Transm (Vienna); 2018 Mar; 125(3):431-447. PubMed ID: 28540422 [TBL] [Abstract][Full Text] [Related]
59. Functional Dopaminergic Neurons in Substantia Nigra are Required for Transcranial Magnetic Stimulation-Induced Motor Plasticity. Hsieh TH; Huang YZ; Rotenberg A; Pascual-Leone A; Chiang YH; Wang JY; Chen JJ Cereb Cortex; 2015 Jul; 25(7):1806-14. PubMed ID: 24451657 [TBL] [Abstract][Full Text] [Related]
60. Synaptic relationships between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum in monkey. Smith Y; Bennett BD; Bolam JP; Parent A; Sadikot AF J Comp Neurol; 1994 Jun; 344(1):1-19. PubMed ID: 7914894 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]